FDA clears Abbott's ovarian cancer diagnostic

06/3/2010 | Canadian Business

Abbott Laboratories said it received FDA clearance for the Architect HE4 blood test, which is designed to track ovarian cancer progression or recurrence. The product is already approved in Europe as well as in some countries in Asia and Latin America.

View Full Article in:

Canadian Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA